Targeting eosinophils by active vaccination against interleukin-5 reduces basophil counts in horses with insect bite hypersensitivity in the 2nd year of vaccination.


Journal

Veterinary journal (London, England : 1997)
ISSN: 1532-2971
Titre abrégé: Vet J
Pays: England
ID NLM: 9706281

Informations de publication

Date de publication:
10 2022
Historique:
received: 02 05 2022
revised: 14 09 2022
accepted: 16 09 2022
pubmed: 21 9 2022
medline: 30 9 2022
entrez: 20 9 2022
Statut: ppublish

Résumé

Previously, virus-like particle (VLP)-based self-vaccinations targeting interleukin (IL)-5 or IL-31 have been suggested to treat equine insect bite hypersensitivity (IBH), a seasonal recurrent allergic dermatitis in horses. The IL-5-targeting equine vaccine significantly reduced blood eosinophil counts in horses, similar to human monoclonal antibodies targeting IL-5 or the IL-5 receptor alpha (IL-5Rα). Previous studies in humans have also reported an additional effect on reduction of basophil counts. The aim of the present study was to evaluate whether an equine anti-IL-5 vaccine affected blood basophil counts. Horses with IBH were followed in a 3-year trial consisting of a placebo administered in the 1st year, followed by vaccination using an equine (e)IL-5-VLP vaccine in the 2nd and 3rd years. There was a strong reduction in circulating eosinophil counts after vaccination against IL-5. Additionally, there were reduced basophil counts, but only in the 3rd year of the study, suggesting a bystander effect of the anti-IL-5 vaccine on basophil counts.

Identifiants

pubmed: 36126798
pii: S1090-0233(22)00111-3
doi: 10.1016/j.tvjl.2022.105896
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Interleukin-5 0
Receptors, Interleukin-5 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105896

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement Victoria Fettelschoss, Katharina Birkmann, and Antonia Fettelschoss-Gabriel are involved in the development of therapeutic equines vaccines. Tanya Rhiner and Angelika Schoster have no financial or personal relationships that could inappropriately influence or bias the content of the paper.

Auteurs

Tanya Rhiner (T)

Vetsuisse Faculty, Equine Department University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland; Evax AG, Hörnlistrasse 3, 9542 Münchwilen, Switzerland.

Victoria Fettelschoss (V)

Evax AG, Hörnlistrasse 3, 9542 Münchwilen, Switzerland; University Hospital Zurich, Department of Dermatology, Wagistrasse 18, 8952 Schlieren, Switzerland; Faculty of Medicine, University of Zurich, Switzerland.

Angelika Schoster (A)

Vetsuisse Faculty, Equine Department University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland.

Katharina Birkmann (K)

Evax AG, Hörnlistrasse 3, 9542 Münchwilen, Switzerland; Faculty of Medicine, University of Zurich, Switzerland.

Antonia Fettelschoss-Gabriel (A)

Evax AG, Hörnlistrasse 3, 9542 Münchwilen, Switzerland; University Hospital Zurich, Department of Dermatology, Wagistrasse 18, 8952 Schlieren, Switzerland; Faculty of Medicine, University of Zurich, Switzerland. Electronic address: Antonia.gabriel@usz.ch.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH